Cassava Sciences' stock is highly shorted, with potential reward tied to the upcoming Phase 3 trial results for simufilam.
Cassava Sciences has faced a lot of scrutiny, with key figures resigning and the company settling an SEC penalty. Read what ...
Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024$149.0 Million in Cash and Cash Equivalents at September 30, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback